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Background: Actinic cheilitis (AC) is a potentially malignant disorder of the lip, characterized by epithelial and 
connective tissue alterations caused by chronic exposure to ultraviolet radiation. In the past decades, diverse 
studies have been conducted in lip carcinogenesis and many biomarkers have been identified in lip lesions, yet 
there is no scientific evidence that determines its usefulness in the clinical setting or in histopathological routine. 
Therefore, we conducted the first systematic review in this field to summarize the results of published studies on 
immunohistochemical biomarkers in lip carcinogenesis, to evaluate if there is a marker than can distinguish the 
different histological grades of AC.
Material and Methods: Retrospective studies that investigated immunohistochemical biomarkers in AC defined 
on standardised histological assessment were gathered from five databases and evaluated. Each study was quali-
tatively evaluated using the Critical Appraisal Tools from SUMARI.
Results: The proliferation marker Ki-67 was the most studied biomarker and we observed, through meta-analysis, 
that it was differently expressed between AC and lip cancer, but not in AC subgroups. Most articles had a high 
risk of bias.
Conclusions: In summary, the literature lacks quality follow up studies in actinic cheilitis. Multi-centre cohort 
studies, with patients stratified by treatment type and the use of image analysis software, could be the solution to 
further address the issues of investigating potentially malignant lesions and help change clinical practice, in terms 
of individualizing patients’ treatment and prognosis prediction.
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Introduction
Lip squamous cell carcinoma (LSCC) represents 20-
30% of all oral cavity tumors and it deserves a specific 
attention, especially in its pathogeny, that differs from 
oral squamous cell carcinoma (OSCC) (1). OSCC is re-
lated to chronic consumption of alcohol and tobacco, 
while LSCC is closely related to chronic exposure to 
the ultraviolet (UV) radiation of sun (1). The establish-
ment of LSCC is preceded by clinical and histological 
alterations in the lip, which is known as actinic cheilitis 
(AC). AC is regarded as a potentially malignant lesion 
and it is characterized as a degenerative disorder, affect-
ing mainly white males over 40-years-old, that usually 
work outdoors (2). Histologically, this lesion is charac-
terized by cytological and architectural modifications, 
epithelial dysplasia and solar elastosis (basophilic de-
generation of elastic fibres) (3). 
To facilitate patient management, grading systems for 
oral epithelial dysplasia have been proposed. According 
to the WHO (4), epithelial dysplasia can be character-
ized as mild, moderate or intense, according to cyto-
logical and architectural alterations. However, this sys-
tem cannot predict patient’s prognosis and is regarded 
by pathologists as subjective (5). In 2006, Kujan et al. 
(6) proposed a binary graduation system for oral dys-
plasia, in order to minimize analysis subjectivity. This 
new system preconizes the division of the lesions in two 
subgroups, according to the risk of malignant transfor-
mation (low risk and high risk). 
In the past years, researches have tried to elucidate 
the mechanisms underlying oral epithelial dysplasia. 
Thereby, many different immunohistochemical bio-
markers have been investigated in oral carcinogenesis 
and a compilation of these results has been outputted 
(7); yet, to our best knowledge, there are no systematic 
reviews on biomarkers of lip carcinogenesis, and re-
searchers and practioners are still not able to determine 
which AC cases will undergo malignant transformation.
For this reason, we conducted a systematic review to exam-
ine if there is some immunohistochemical biomarker that 
could be related to the degree of epithelial dysplasia in AC.
Material and Methods
This systematic review was reported according to the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses PRISMA Checklist (available at: http://
www.prisma-statement.org). The review protocol was 
registered at the International Prospective Register of 
Systematic Reviews (PROSPERO) under number CRD 
42017055294.
- Study design
We conducted a systematic review of human studies to 
summarize the results of published studies on immuno-
histochemical biomarkers in lip carcinogenesis, in order 
to evaluate if there is a marker than can distinguish the 
different histological grades of actinic cheilitis (AC).
- Search strategy
We searched and identified articles of the following 
bibliographic databases: PubMed, Scopus, Web of Sci-
ence, ScienceDirect and Scielo. The search included all 
articles published up to April 25th, 2017, with no time 
restrictions. Duplicated references were excluded by a 
reference manager software (Mendeley Desktop ver-
sion 1.17.9).
The search strategy used for PubMed was: ((((((actin-
ic cheilitis[Title/Abstract]) OR actinic cheilosis[Title/
Abstract]) OR solar cheilosis[Title/Abstract]) OR solar 
cheilitis[Title/Abstract]) OR lip carcinogenesis[Title/
Abstract]) OR lip photocarcinogenesis[Title/Abstract]) 
AND immunohistochem*[Title/Abstract]. For the other 
databases we conducted independent searches using the 
first block: (actinic cheilitis OR actinic cheilosis OR 
solar cheilosis OR solar cheilitis OR lip carcinogenesis 
OR lip photocarcinogenesis), in order to maximize the 
inclusion of relevant studies. 
- Inclusion criteria
Prospective and retrospective studies that investigated 
immunohistochemical biomarkers in AC defined on 
standardised histological assessment as outlined by the 
WHO (4) and/or Kujan (6). 
- Exclusion criteria
The following exclusion criteria were applied: (a) Scien-
tific papers that did not report AC histological grading; 
(b) Lack of comparison between biomarkers among AC 
groups or between AC and control (normal lip mucosa 
or lip squamous cell carcinoma); (c) Studies that inves-
tigated immunohistochemical biomarkers in samples 
other than paraffinized material; (d) Reviews, single 
case reports, clinical trials, letters, personal opinions, 
book chapters, and conference abstracts.
- Study selection
The study selection was conducted by two authors (BM 
and TS), who independently reviewed the titles and ab-
stracts of all the papers, and selected the studies that 
met the inclusion criteria. A kappa test was performed 
to verify agreement between authors and we obtained 
a reliable result of 0.87. Afterwards, both authors in-
dependently evaluated all full articles to determine if 
they reported the expression of immunohistochemical 
biomarkers in the subgroups of AC, based on histologi-
cal grading (kappa score = 1). If there were any dis-
agreements between the authors, they were resolved by 
mutual consensus. Final selection was always based on 
the full-text of the publication.
- Data collection
Two authors (BM and TS) collected the information 
from the included papers. The following information 
was gathered and presented in tables: study character-
istics (author, year of publication, country); population 
(sample size, cases of AC, LSCC and normal lip con-
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Model to estimate the amount of residual heterogeneity 
(tau2) and unaccounted variability (I2) among groups. 
The analysis was performed with the R software, pack-
age metafor 1.9-8.
- Risk of bias in individual studies
Each selected study was qualitatively evaluated using 
the Critical Appraisal Tools from SUMARI (System 
for the Unified Management, Assessment and Review 
of Information), proposed by the Joana Briggs Institute 
(available at: http://joannabriggs.org/research/critical-
appraisal-tools.html). Since almost all cases comprised 
retrospective studies, with samples chosen by con-
venience and lack of follow-up, we used the Critical 
Appraisal Tool for Case Series. This type of study is 
described as the kind in which “only patients with the 
outcome are sampled (either those who have an expo-
sure or those who are selected without regard to expo-
sure), which does not permit calculation of an absolute 
risk” (8). In our case, the exposure is the lesion actinic 
cheilitis. The evaluated items were scored “Yes”, “No” 
or “Unclear” for each paper individually (Table 1).
trols); type of histological grading performed; immuno-
histochemical biomarkers that were analysed; expres-
sion of biomarkers in each subgroup (AC, LSCC and 
control); statistical tests performed; main conclusions. 
A partial grey literature search was performed using 
Google Scholar in order to investigate detailed results 
from PhD and Master’s degree thesis and dissertations, 
and perform the meta-analysis. 
- Meta-analysis 
Due to high heterogeneity in immunopositive cells 
counting/scoring for the studied biomarkers and con-
trasting results presentation in the articles, we included 
only the protein Ki-67 for the meta-analysis. This was 
one of the most studied proteins and the only one that 
had a standardized analysis among the studies. To be in-
cluded for meta-analysis, the articles (or their respective 
thesis/dissertations) had to report the mean and standard 
deviation of Ki-67 immunopositive cells in each of the 
following groups: control, mild dysplasia AC, moderate 
dysplasia AC, severe dysplasia AC, low grade LSCC, 
moderate/high grade LSCC. We used a Mixed-effects 










































































































































































































































1. Were there clear criteria for 
inclusion in the case series?                            
2. Was the condition mea-
sured in a standard, reliable 
way for all participants in-
cluded in the case series?
                           
3. Were valid methods used 
for identification of the condi-
tion for all participants in-
cluded in the case series?
                           
4. Did the case series have con-
secutive inclusion of participants?                            
5. Did the case series have com-
plete inclusion of participants?                            
6. Was there clear reporting 
of the demographics of the 
participants in the study?
                           
7. Was there clear reporting 
of clinical information of the 
participants?
                           
8. Were the outcomes or follow up 
results of cases clearly reported?                            
9.. Was there clear reporting of 
the presenting site(s)/clinic(s) 
demographic information?
                           
10. Was statistical analysis 
appropriate?                            
Legend: Yes   No  Unclear  
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Results
- Study selection
1088 articles were identified across the five electronic 
databases. After removing the duplicates, 822 articles 
remained. A comprehensive evaluation of the titles 
and abstracts resulted in the exclusion of 746 articles, 
with the remaining 76 articles being allocated to full 
text in-depth review. This process led to the exclu-
sion of 49 studies. Finally, 27 articles were retained 
for qualitative analysis and three articles were selected 
for meta-analysis. A flow chart detailing the process of 
identification, inclusion, and exclusion of the studies is 
shown in Fig. 1.
- Study characteristics 
All reviewed articles comprised retrospective studies 
(10-36) (Table 2). The studies presented a great geo-
graphic polarization; from the 27 analyzed articles, 25 
where originated from Brazil, one from Germany and 
one from the USA. The included studies were pub-
lished between 2003 and 2017. The number of AC cases 
in each study varied from 10 to 70, while LSCC cases 
went from 0 to 65 cases. Forty-one  [41] different pro-
teins were researched in these articles, and the relation 
between these proteins expressions among LSCCs and 
ACs was investigated in 20 papers. The mean number of 
studied ACs was 34.5 cases per article, while the mean 
of LSCC was 32 cases. Only five articles used the bi-
nary grading system proposed by Kujan et al. (Table 1). 
Among the studied biomarkers, the ones that were most 
investigated were DNA repair proteins, with 12 anti-
bodies assessed. The inflammatory markers were the 
second most assessed group. Other groups of proteins 
were also analyzed, including apoptosis markers, me-
talloproteins, cell cycle markers, growth factors, neural 
and muscle markers (Fig. 2). This variety of biomarkers 
hampered any analyses between the articles. 
Fig. 1: Flow diagram for study selection.
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Quantitative analysis – 500 
cells counted in 5 fields at 
400x
HDAC1 + + + +
HDAC2 +++ +++ +++ +







Quantitative in five fields 
– represented by positivity 
index
VEGF- c  + + + X
HIF1a + + + X







Quantitative in four ran-
domized fields presented as 
means by epithelial layers
Cyclin d1 + ++ +++ ++++
Ki-67 + + + ++++







Cytokeratins were observed 
in epithelial layers in 10 
fields and for Ki-67 a cell 
proliferation index was 
calculated (epithelial posi-
tive cells x the total number 
of epithelial cells)
CK10 + + + ++++
CK13 + + + ++++









Semi-quantitative - 0, no 
tumor cells stained; 1, 
<25% of cells stained; and 
2,>25% of cells stained. 
Staining intensity was 
scored as: 0, no staining; 1, 
weak staining; 2, moder-
ate staining; and 3, strong 
staining.
HLAG + + + ++++
HLAE + + + ++++







Quantitative by mean - ran-
domized fields until a num-
ber of 1000 cells 
p53 + + + +
p21 ++++ ++++ ++++ +





Semi-quantitative score - 
percentage of positive cells 
in a 200× magnification 
field (0=0 % stained cells 
 1=1–50 % cells, 
2=51–100 % of cells). 
CD31 was used to calculate 
microvascular density in 
hotspots.
VGRF 1* ++++ ++++ ++++ +
VGRF2 ++++ ++++ ++++  







Quantitative by mean – 
positive cells counted in 10 
fields at 200x magnification
CD1a + + + x





Quantitative – positive cells 
were evaluated in 5 equi-
distant fields (400x). 
MMP1 + + + +
MMP2 ++++ ++++ ++++ +
MMP9 ++++ ++++ ++++ +
Ki-67 +a +a +a +a







Semi-quantitative score - 
(1) 1–30% of positive cellls 
(2) 31–60% (3) more than 
60%
  High risk Low risk
Galectin 1  +  +
Galectin 3  +  +++
Galectin 7  +  +








by spots - seven fields 
quantified comprising an 
area of 1mm2
 High risk  LSCC
CD1a ++++  +
CD83 +  +
Table 2: Details of selected studies.
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Quantitative analysis by 
percentage of positive cells 
in ten consecutive fields of 
400x
p63 + + + ++++
MDM2 ++++ + + +
hMHL1 + + + +






Quantitative analysis -1,000 
cells were counted at 400× 
and presented as percentage 
of positive cells 
MDM2 + + + +





Ki-67 quantitative analyses, 
until 1,000 cells/ TGF-b1 
and Elastin semi-quantita-
tive analysis, presented as 
scores
Ki-67 + ++ +++ ++++
Elastin + + + +







Quantitative analysis until 
1,000 cells (400x) – pre-
sented as percentages and 
scores (1 <50%  reduced 
expression; 25%–75% 
normal 
Expression; 3 > 75% Over-
expression)
MLH1 +++ ++ ++ +








- 10 fields at 100x magnifi-
cation, degree of elastosis 
was evaluated according to 
scores
Elastin +% +% +% x
Von bub-
noff et al., 
2012
Germany WHO 25/x
Quantitative analysis, - 
stratified as density of in-
flammatory infiltrate posi-
tive cells/mm2
IDO + ++ +++ x
CD11 NOT RELATED TO DYSPLASIA GROUPS
S100 NOT RELATED TO DYSPLASIA GROUPS
CD68 NOT RELATED TO DYSPLASIA GROUPS
CD1a NOT RELATED TO DYSPLASIA GROUPS
Souza et al, 
2010 Southeast WHO 29/29
Quantitative analysis with 
an ocular lattice – present-
ed by mean
CD31 + + + +





Qualitative analysis in 





Quantitative analysis in 
10 representative and con-
secutive microscopic high-
power fields (x400)
Triptase + + + +++
CD117 + + + +
CD31 + + + +








– 0 negative; 1 up to 5% of 
positive cells; 2  5% - 50% 
of positive cells; 3 more 
than 50% of positive cells







Semi-quantitative analysis - 
negative (0, not detectable); 
1 (detectable but less than 
50% of tumoral or atypical 
cells stained); 2 (labeling 
of more than 50% and less 
than 75% of tumoral or 
atypical cells); and 3 (wide-
ly and highly expressed in 
more than 75% of the tu-
moral or atypical cells)
B-catenin
Low risk High risk LSCC
+ + +
MMP3 + + +
Wnt5a +++ ++ +
Table 2 cont.: Details of selected studies.
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Quantitative analysis – 
mean percentage of positive 
cells from 15 random areas 
at 400x








sis - percentage of positive 
cells determined from the 
percentage of total positive 
and negative cells derived 
from 10 random areas at 
×400 magnification, then 
classified as scores
p53 +* +* +* X
MDM2 +* +* +* X






Qualitative analysis in 
nucleus and cytoplasm and 
in epithelium layers
STAT3 -- -- -- --












tive analysis - percentage 
of p53-positive cells and 
intensity of stain in 10 
consecutive 400x fields







Quantitative analysis - 
percentage of positive cells 
in a 400x field
hMSH2 + + + +
+ Indicates similar protein expression between groups
++ and +++ indicate higher protein expression in the group (statistically significant)
X No cases
* Statistically significant – correlated among groups (Spearman’s correlation)
-- No quantitative analysis
a Proliferation index (Ki-67) and myofibroblasts (α-SMA) increased with the worsening of dysplasia group and in LSCC, but it was not statisti-
cally significant
Table 2 cont.: Details of selected studies.
Fig. 2: Number of studied cases according to protein groups.
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- Risk of bias
After analyzing all included studies with SUMARI 
critical appraisal tool, we observed that most articles 
(n=22) had unclear criteria for inclusion of the cases. We 
considered a clear inclusion criterion when the study re-
ported when the cases were diagnosed, where they were 
collected and what were the sample inclusion/exclusion 
criteria (even if it was a convenience sample).  Also, 
only three studies reported to have consecutive inclu-
sion of cases. However, all studies reported a reliable 
measurement of AC degrees of dysplasia according to 
the grading systems proposed by WHO (4) and Kujan 
et al (6).
Thirteen articles reported the patients’ demographics, 
while clinical information was available in only four 
of the reviewed studies. Information regarding the pa-
tient’s outcome/follow-up was available in only one 
study (9) and partially available in another one (10). 
Almost all studies reported to use clear statistical meth-
ods to compare the variables, however they were very 
diverse, since the researchers applied different method-
ologies for cell counting, with no clear cutoff of what 
was positive/negative or low/high. Also, maybe due to 
limited number of cases, authors tended to group AC 
cases for statistical analysis, and this grouping was very 
heterogeneous among studies. 
- Meta-analysis
Three studies were selected for meta-analysis (11,12,23). 
We compared the mean expression of Ki-67 among 
the groups of AC, LSCC and control and observed a 
high heterogeneity among the studies (tau2=241.02; 
I2=95.91%). We observed that Ki-67 mean expression 
was similar in control groups and was higher in LSCC 
than in AC. However, it varied remarkably among AC 
subgroups. This information is summarized in a forest 
plot in Fig. 3.
Discussion
One of the main purposes of investigating immunohis-
tochemical biomarkers in lip lesions is observing if there 
are differences between protein expressions in different 
grades of AC or between AC and LSCC or control/nor-
mal lip. Usually, this is done not for diagnostic purposes, 
but with the expectation to develop future prognostic 
markers, which could possibly set apart cases that will 
undergo malignant transformation. 
In the past two decades a significant number of studies 
have been conducted in lip carcinogenesis and many bio-
markers have been identified in lip lesions, yet researchers 
are still not able to determine its usefulness in the clinical 
setting or in histopathological routine (37). The histologi-
cal grading system proposed by WHO (4) for epithelial 
dysplasia in AC is extensively used by oral pathologists, 
anyhow, clinical experience has shown that even cases of 
mild oral dysplasia can develop into LSCC (38). In 2006, 
Kujan et al. (6) proposed a new binary grading system 
for AC, however a decade later few studies applied this 
system for histological assessment (5,39). 
In this review, only few papers investigated the same bio-
markers, which made it impractical to make comparisons 
between studies. The proliferation marker Ki-67 was 
the most studied biomarker, anyhow only three papers 
studying this protein met the inclusion criteria for meta-
analysis. We observed that Ki-67 is differently expressed 
among AC and control and between AC and LSCC, 
however its expression was highly variable among AC 
groups.
Despite we have identified many studies in this review, 
almost all of them comprise case series, with cross-sec-
tional analyses, lacking quality follow-up data for AC 
cases and are therefore unsuitable to in use in prognosis 
analysis. We recognize that this is one of the main issues 
of studying oral potentially malignant disorders, since 
Fig. 3: Forest plot showing the differences in Ki-67 expression among control (no number), AC with mild dysplasia (.1), 
AC with moderate dysplasia (.2), AC with severe dysplasia (.3), low grade LSCC (.4) and moderate/high grade LSCC (.5).
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they may or not undergo malignant transformation in an 
unknown period of time, and it is challenging to follow-
up patients continuously. 
Also, most reviewed studies failed to specify the inclu-
sion criteria for studied cases and samples were chosen 
by convenience, which is a potential source of bias and it 
can reduce the level of evidence of the studies.  Besides, 
many articles did not report important clinic and demo-
graphic data of the patients, nor did they report the pre-
senting site’s clinic/demographic information. Therefore, 
it is not possible to make comparisons between patient’s 
characteristics and expression of immunohistochemical 
biomarkers. Furthermore, the literature is inconsistent 
regarding the evaluation of biomarkers positivity or low/
high expression, since researchers uses different quanti-
tative or semi-quantitative methodologies for cell evalua-
tion, which makes it difficult to compare studies with the 
same biomarkers. 
Notwithstanding, another possible source of bias is 
the statistical analysis performed for each study. Even 
though most authors statistically analysed their results, 
we observed a tendency in grouping AC subgroups (e.g. 
all cases of AC independently of dysplasia grading) and 
comparing it only to LSCC or control, to achieve sta-
tistically significant results. This could be due to small 
sample sizes, as it could possibly be related to selective 
reporting bias, which may happen as a result of the belief 
that scientific journals will not to accept papers report-
ing only “negative” results (not statistically significant). 
Additionally, nearly all evaluated studies are not repli-
cable or reproducible, since important data are often not 
reported. According to Peng [2015] (40), there are two 
major components to a reproducible study: that the raw 
data from the experiment are available; and that the sta-
tistical code and documentation to reproduce the analysis 
are also available. 
At last, we acknowledge another risk of bias within this 
review, since almost all included studies are from Brazil-
ian research groups. This can be explained by the fact 
that in tropical countries, rural workers are chronically 
exposed to high levels of solar radiation throughout the 
year, which explains an AC prevalence of up to 28.4% in 
Brazilian populations (41). Considering that, a great num-
ber of studies in this field are conducted in this country. 
Also, we have thoroughly analysed all published studies 
in AC and although there are papers from USA, Chile, 
Australia, Greece, Spain and Germany, for example, 
only two of them met the inclusion criteria in this review. 
The other researches that investigated biomarkers in AC 
did not report comparisons between epithelial dysplasia 
groups and therefore were excluded.  
As regards the meta-analysis, we also acknowledge its 
limitation. Since only three articles could be included 
for statistical analysis, we observed high heterogeneity 
among results, specially between AC groups, and this 
may not represent the reality of Ki-67 staining in AC or 
LSCC. One of the studies that investigated this protein 
(10) had to be excluded from meta-analysis since we be-
lieve the authors analysed the same sample used in their 
previous study (11), which was included. 
- Implications for research and practice
In this review, we have identified 76 studies that inves-
tigated biomarkers in the field of lip carcinogenesis. De-
spite this significant number, well documented cohort 
studies are still limited. We still ought to understand the 
behaviour of AC and its progression to cancer, in order to 
apply it clinically. We emphasize the difficulty in access-
ing complete follow-up data and highlight the need for 
further clinical research in potentially malignant disor-
ders. As suggested in a systematic review by Smith et al. 
(7), multi-centre cohort studies, with patients stratified 
by treatment type, could be the solution to further ad-
dress the issues of investigating those lesions. 
We recommend that in studies of biomarkers of lip car-
cinogenesis histological grading is performed for AC 
and LSCC, preferentially using more than one grading 
system. Also, comparisons with normal epithelium are 
indispensable. Thoroughly describing the methodology 
used for quantifying the antibodies is crucial for repro-
ducibility of the study and, ideally, a unified methodology 
should be adopted. Maybe with the aid of an image soft-
ware, to reduce examiners’ observation variability, this 
could be achieved. Likewise, results should be described 
more carefully, with tables showing the results for each 
AC and LSCC subgroup, as well as control groups. Clinic 
and demographic information are also important to be 
described.
Conclusions
We observed that the different studied proteins are simi-
larly expressed in AC epithelial dysplasia grades, there-
fore are not useful in differentiating them. However, the 
potential use of some biomarkers to differentiate AC and 
LSCC has been demonstrated. We believe that soon some 
of them could become useful in identifying cancer risk 
in patients with actinic cheilitis. If we can develop reli-
able and reproducible follow-up studies, we will be able 
to change clinical practice in terms of individualizing pa-
tients’ treatment and prognosis prediction. Clearly, fur-
ther research is needed to exploit the many possibilities 
in lip carcinogenesis.
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